 Mark Connelly
Concepts (347)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Migraine Disorders | 11 | 2022 | 15 | 5.010 |
Why?
| | Pain | 15 | 2023 | 57 | 3.700 |
Why?
| | Arthritis, Juvenile | 11 | 2023 | 31 | 2.870 |
Why?
| | Adolescent | 45 | 2023 | 2197 | 2.430 |
Why?
| | Pain Measurement | 12 | 2021 | 45 | 2.430 |
Why?
| | Humans | 79 | 2023 | 6896 | 2.300 |
Why?
| | Telemedicine | 4 | 2022 | 59 | 2.100 |
Why?
| | Child | 48 | 2023 | 3364 | 2.030 |
Why?
| | Pain Management | 11 | 2023 | 27 | 1.970 |
Why?
| | Chronic Pain | 7 | 2023 | 32 | 1.970 |
Why?
| | Headache | 5 | 2017 | 14 | 1.950 |
Why?
| | Female | 46 | 2022 | 3525 | 1.830 |
Why?
| | Male | 45 | 2022 | 3337 | 1.760 |
Why?
| | Activities of Daily Living | 6 | 2019 | 11 | 1.720 |
Why?
| | Analgesics, Opioid | 4 | 2021 | 42 | 1.630 |
Why?
| | Surveys and Questionnaires | 12 | 2022 | 274 | 1.580 |
Why?
| | Rheumatology | 4 | 2023 | 4 | 1.450 |
Why?
| | Adaptation, Psychological | 9 | 2021 | 39 | 1.300 |
Why?
| | Fibromyalgia | 4 | 2023 | 4 | 1.280 |
Why?
| | Quality of Life | 9 | 2023 | 140 | 1.180 |
Why?
| | Pain, Postoperative | 3 | 2014 | 35 | 1.120 |
Why?
| | Arthralgia | 3 | 2019 | 3 | 1.060 |
Why?
| | Parents | 3 | 2022 | 157 | 0.980 |
Why?
| | Emergency Service, Hospital | 6 | 2023 | 130 | 0.940 |
Why?
| | Medical Records | 4 | 2014 | 14 | 0.900 |
Why?
| | Patient Acceptance of Health Care | 2 | 2020 | 35 | 0.870 |
Why?
| | Self Report | 2 | 2020 | 42 | 0.850 |
Why?
| | Pediatrics | 5 | 2021 | 186 | 0.820 |
Why?
| | Firearms | 1 | 2022 | 7 | 0.810 |
Why?
| | Wounds, Gunshot | 1 | 2022 | 12 | 0.810 |
Why?
| | Delivery of Health Care | 4 | 2023 | 33 | 0.800 |
Why?
| | Membrane Proteins | 9 | 2001 | 54 | 0.800 |
Why?
| | Emergency Medical Services | 1 | 2021 | 14 | 0.790 |
Why?
| | Patient Education as Topic | 3 | 2019 | 53 | 0.790 |
Why?
| | Receptors, Immunologic | 9 | 2001 | 11 | 0.780 |
Why?
| | Receptors, Lipoprotein | 9 | 2001 | 9 | 0.780 |
Why?
| | Monitoring, Ambulatory | 1 | 2020 | 4 | 0.760 |
Why?
| | Smartphone | 1 | 2020 | 6 | 0.750 |
Why?
| | Emotions | 5 | 2017 | 22 | 0.710 |
Why?
| | Headache Disorders | 2 | 2019 | 3 | 0.700 |
Why?
| | Rheumatic Diseases | 1 | 2019 | 2 | 0.700 |
Why?
| | Dihydroergotamine | 1 | 2019 | 1 | 0.700 |
Why?
| | Massage | 1 | 2019 | 1 | 0.700 |
Why?
| | Aromatherapy | 1 | 2019 | 1 | 0.700 |
Why?
| | Psychotherapy | 1 | 2019 | 4 | 0.700 |
Why?
| | Self-Assessment | 2 | 2010 | 5 | 0.690 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2019 | 8 | 0.690 |
Why?
| | Inappropriate Prescribing | 1 | 2019 | 27 | 0.690 |
Why?
| | Decision Support Systems, Clinical | 1 | 2019 | 17 | 0.690 |
Why?
| | Primary Health Care | 1 | 2019 | 42 | 0.680 |
Why?
| | Clinical Protocols | 1 | 2019 | 29 | 0.680 |
Why?
| | Ambulatory Care | 1 | 2019 | 45 | 0.670 |
Why?
| | Retrospective Studies | 10 | 2021 | 1296 | 0.660 |
Why?
| | Stress, Psychological | 2 | 2011 | 32 | 0.660 |
Why?
| | Program Evaluation | 1 | 2019 | 45 | 0.660 |
Why?
| | Affect | 2 | 2010 | 8 | 0.640 |
Why?
| | Health Personnel | 3 | 2022 | 25 | 0.630 |
Why?
| | Pupil | 2 | 2015 | 3 | 0.620 |
Why?
| | Reflex, Pupillary | 2 | 2015 | 3 | 0.620 |
Why?
| | Prospective Studies | 10 | 2020 | 525 | 0.610 |
Why?
| | Musculoskeletal Pain | 4 | 2023 | 5 | 0.600 |
Why?
| | School Nursing | 1 | 2017 | 5 | 0.600 |
Why?
| | Students | 1 | 2017 | 34 | 0.580 |
Why?
| | Immunization | 1 | 2016 | 25 | 0.550 |
Why?
| | Young Adult | 6 | 2021 | 647 | 0.540 |
Why?
| | Neoplastic Cells, Circulating | 4 | 2017 | 4 | 0.510 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2014 | 2 | 0.490 |
Why?
| | Arthritis, Rheumatoid | 3 | 2014 | 9 | 0.480 |
Why?
| | Scoliosis | 1 | 2014 | 6 | 0.470 |
Why?
| | Amitriptyline | 1 | 2013 | 4 | 0.470 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2013 | 5 | 0.460 |
Why?
| | Electronic Health Records | 2 | 2014 | 64 | 0.440 |
Why?
| | Hospitals | 2 | 2023 | 36 | 0.410 |
Why?
| | Perception | 1 | 2012 | 6 | 0.410 |
Why?
| | Adult | 11 | 2021 | 1181 | 0.410 |
Why?
| | Health Services | 1 | 2012 | 6 | 0.410 |
Why?
| | Quality of Health Care | 1 | 2011 | 13 | 0.390 |
Why?
| | Attitude to Health | 2 | 2016 | 26 | 0.390 |
Why?
| | Societies, Medical | 1 | 2011 | 51 | 0.380 |
Why?
| | Acupuncture Therapy | 2 | 2021 | 3 | 0.380 |
Why?
| | Anemia, Sickle Cell | 3 | 2006 | 17 | 0.380 |
Why?
| | Treatment Outcome | 10 | 2022 | 622 | 0.380 |
Why?
| | Health Behavior | 1 | 2011 | 50 | 0.370 |
Why?
| | Lipoproteins, HDL | 6 | 2001 | 8 | 0.370 |
Why?
| | Child, Preschool | 6 | 2023 | 1569 | 0.360 |
Why?
| | Pilot Projects | 5 | 2021 | 120 | 0.360 |
Why?
| | Tension-Type Headache | 1 | 2009 | 1 | 0.350 |
Why?
| | Humidity | 1 | 2009 | 3 | 0.350 |
Why?
| | Weather | 1 | 2009 | 4 | 0.350 |
Why?
| | Severity of Illness Index | 6 | 2014 | 149 | 0.340 |
Why?
| | Pain Threshold | 1 | 2009 | 3 | 0.340 |
Why?
| | Predictive Value of Tests | 5 | 2014 | 99 | 0.330 |
Why?
| | Reproducibility of Results | 3 | 2020 | 199 | 0.320 |
Why?
| | Cholesterol Esters | 5 | 2001 | 5 | 0.310 |
Why?
| | Cross-Sectional Studies | 4 | 2020 | 336 | 0.300 |
Why?
| | Disability Evaluation | 5 | 2022 | 8 | 0.300 |
Why?
| | Social Control, Informal | 1 | 2007 | 1 | 0.300 |
Why?
| | Expressed Emotion | 1 | 2007 | 1 | 0.300 |
Why?
| | Affective Symptoms | 1 | 2007 | 3 | 0.300 |
Why?
| | Mass Screening | 2 | 2021 | 35 | 0.290 |
Why?
| | Health Status | 2 | 2014 | 25 | 0.290 |
Why?
| | Pain, Intractable | 1 | 2006 | 1 | 0.290 |
Why?
| | Weight Reduction Programs | 2 | 2020 | 25 | 0.280 |
Why?
| | Musculoskeletal Diseases | 1 | 2006 | 2 | 0.280 |
Why?
| | Therapy, Computer-Assisted | 1 | 2006 | 2 | 0.280 |
Why?
| | Software | 1 | 2006 | 30 | 0.270 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 3 | 2020 | 7 | 0.260 |
Why?
| | Feasibility Studies | 3 | 2021 | 58 | 0.260 |
Why?
| | Middle Aged | 8 | 2019 | 608 | 0.250 |
Why?
| | Follow-Up Studies | 4 | 2020 | 304 | 0.250 |
Why?
| | Curriculum | 2 | 2021 | 22 | 0.240 |
Why?
| | Lupus Erythematosus, Systemic | 2 | 2015 | 15 | 0.240 |
Why?
| | Cholesterol | 5 | 2001 | 9 | 0.230 |
Why?
| | Apolipoprotein A-I | 2 | 2000 | 2 | 0.230 |
Why?
| | Cell Separation | 2 | 2013 | 7 | 0.230 |
Why?
| | Risk Assessment | 2 | 2022 | 137 | 0.220 |
Why?
| | Autism Spectrum Disorder | 1 | 2023 | 32 | 0.220 |
Why?
| | Rural Population | 1 | 2023 | 42 | 0.220 |
Why?
| | Social Support | 2 | 2021 | 25 | 0.220 |
Why?
| | Suicide | 1 | 2023 | 5 | 0.220 |
Why?
| | Hospitals, Pediatric | 2 | 2022 | 187 | 0.220 |
Why?
| | Fatigue | 3 | 2023 | 15 | 0.210 |
Why?
| | Life Style | 2 | 2021 | 24 | 0.210 |
Why?
| | Age Factors | 3 | 2022 | 210 | 0.210 |
Why?
| | Registries | 2 | 2019 | 92 | 0.210 |
Why?
| | Avoidance Learning | 1 | 2022 | 6 | 0.210 |
Why?
| | Receptors, Scavenger | 9 | 2001 | 9 | 0.210 |
Why?
| | Scavenger Receptors, Class B | 9 | 2001 | 9 | 0.210 |
Why?
| | Technology | 1 | 2022 | 3 | 0.200 |
Why?
| | Safety | 1 | 2022 | 14 | 0.200 |
Why?
| | Suicidal Ideation | 1 | 2022 | 6 | 0.200 |
Why?
| | United States | 2 | 2022 | 669 | 0.200 |
Why?
| | C-Reactive Protein | 2 | 2019 | 16 | 0.200 |
Why?
| | Biomarkers | 3 | 2019 | 136 | 0.200 |
Why?
| | Extracellular Space | 1 | 2001 | 5 | 0.190 |
Why?
| | Recombinant Fusion Proteins | 1 | 2001 | 13 | 0.190 |
Why?
| | Physicians | 1 | 2021 | 23 | 0.190 |
Why?
| | Pandemics | 1 | 2022 | 82 | 0.190 |
Why?
| | Adrenal Glands | 1 | 2000 | 6 | 0.190 |
Why?
| | Mobile Applications | 1 | 2021 | 16 | 0.190 |
Why?
| | Mood Disorders | 2 | 2013 | 7 | 0.190 |
Why?
| | Practice Patterns, Physicians' | 1 | 2021 | 85 | 0.190 |
Why?
| | Cholesterol, HDL | 1 | 2000 | 10 | 0.190 |
Why?
| | Patient Participation | 1 | 2020 | 15 | 0.190 |
Why?
| | Transcutaneous Electric Nerve Stimulation | 1 | 2020 | 1 | 0.190 |
Why?
| | Nerve Block | 1 | 2020 | 1 | 0.190 |
Why?
| | Prochlorperazine | 1 | 2020 | 1 | 0.190 |
Why?
| | Ketorolac | 1 | 2020 | 1 | 0.190 |
Why?
| | Headache Disorders, Primary | 1 | 2020 | 1 | 0.190 |
Why?
| | Diphenhydramine | 1 | 2020 | 2 | 0.190 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2020 | 20 | 0.180 |
Why?
| | Child, Hospitalized | 1 | 2020 | 26 | 0.180 |
Why?
| | Biomarkers, Tumor | 2 | 2017 | 65 | 0.180 |
Why?
| | Magnesium | 1 | 2019 | 2 | 0.180 |
Why?
| | Sleep Wake Disorders | 2 | 2019 | 22 | 0.180 |
Why?
| | Internet | 1 | 2019 | 17 | 0.170 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2019 | 7 | 0.170 |
Why?
| | Risk Factors | 2 | 2019 | 487 | 0.170 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 48 | 0.170 |
Why?
| | Infusions, Intravenous | 1 | 2019 | 26 | 0.170 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 46 | 0.170 |
Why?
| | Glycoproteins | 1 | 2019 | 9 | 0.170 |
Why?
| | Health Services Accessibility | 1 | 2019 | 39 | 0.170 |
Why?
| | Qualitative Research | 3 | 2023 | 24 | 0.170 |
Why?
| | Kidney Diseases | 1 | 2019 | 71 | 0.160 |
Why?
| | Cardiovascular Diseases | 1 | 2019 | 48 | 0.160 |
Why?
| | Schools | 1 | 2019 | 56 | 0.160 |
Why?
| | Animals | 8 | 2001 | 729 | 0.160 |
Why?
| | Antirheumatic Agents | 2 | 2019 | 12 | 0.160 |
Why?
| | Pediatric Obesity | 1 | 2020 | 137 | 0.150 |
Why?
| | Negotiating | 1 | 2017 | 2 | 0.150 |
Why?
| | Peer Group | 1 | 2017 | 7 | 0.150 |
Why?
| | Interpersonal Relations | 1 | 2017 | 11 | 0.150 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2017 | 3 | 0.150 |
Why?
| | Lung Neoplasms | 1 | 2017 | 23 | 0.150 |
Why?
| | School Health Services | 1 | 2017 | 9 | 0.150 |
Why?
| | Caregivers | 2 | 2010 | 40 | 0.150 |
Why?
| | Adolescent Behavior | 1 | 2017 | 43 | 0.140 |
Why?
| | Aged | 5 | 2019 | 378 | 0.140 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 108 | 0.140 |
Why?
| | Sleep | 2 | 2021 | 37 | 0.140 |
Why?
| | Infant | 3 | 2016 | 1446 | 0.140 |
Why?
| | Health Expenditures | 1 | 2016 | 15 | 0.140 |
Why?
| | COS Cells | 6 | 2001 | 19 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2016 | 2 | 0.140 |
Why?
| | Health Education | 2 | 2014 | 26 | 0.130 |
Why?
| | Inflammation Mediators | 1 | 2015 | 8 | 0.130 |
Why?
| | Recurrence | 2 | 2006 | 110 | 0.130 |
Why?
| | Colorectal Neoplasms | 1 | 2016 | 29 | 0.130 |
Why?
| | Time Factors | 1 | 2016 | 250 | 0.130 |
Why?
| | Iris | 1 | 2015 | 1 | 0.130 |
Why?
| | Eye | 1 | 2015 | 3 | 0.130 |
Why?
| | Upper Extremity Deep Vein Thrombosis | 1 | 2015 | 2 | 0.130 |
Why?
| | Catheterization, Central Venous | 1 | 2015 | 18 | 0.120 |
Why?
| | Problem Solving | 1 | 2014 | 2 | 0.120 |
Why?
| | Writing | 1 | 2014 | 2 | 0.120 |
Why?
| | Self Disclosure | 1 | 2014 | 4 | 0.120 |
Why?
| | Prognosis | 2 | 2017 | 211 | 0.120 |
Why?
| | Medical Informatics | 1 | 2014 | 7 | 0.120 |
Why?
| | CD-ROM | 1 | 2014 | 1 | 0.120 |
Why?
| | Early Medical Intervention | 1 | 2014 | 2 | 0.120 |
Why?
| | Biological Products | 1 | 2014 | 3 | 0.120 |
Why?
| | Pleural Effusion, Malignant | 1 | 2013 | 1 | 0.120 |
Why?
| | Brain | 2 | 2012 | 80 | 0.120 |
Why?
| | Self Care | 1 | 2014 | 22 | 0.120 |
Why?
| | Epithelial Cells | 1 | 2013 | 7 | 0.110 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2013 | 8 | 0.110 |
Why?
| | Infant, Newborn | 1 | 2016 | 816 | 0.110 |
Why?
| | Sensitivity and Specificity | 2 | 2013 | 150 | 0.110 |
Why?
| | Communication | 2 | 2023 | 46 | 0.110 |
Why?
| | Social Adjustment | 1 | 2012 | 4 | 0.110 |
Why?
| | Memory, Short-Term | 1 | 2012 | 3 | 0.110 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2012 | 4 | 0.110 |
Why?
| | Cell Membrane | 3 | 2001 | 8 | 0.110 |
Why?
| | Cognition | 1 | 2012 | 32 | 0.100 |
Why?
| | Osteoarthritis, Knee | 1 | 2012 | 1 | 0.100 |
Why?
| | Parent-Child Relations | 1 | 2012 | 37 | 0.100 |
Why?
| | Neoplasms | 1 | 2013 | 128 | 0.100 |
Why?
| | Precipitating Factors | 1 | 2011 | 1 | 0.100 |
Why?
| | Obesity | 1 | 2012 | 125 | 0.090 |
Why?
| | Mice | 3 | 2001 | 348 | 0.090 |
Why?
| | Cytoplasm | 2 | 2001 | 7 | 0.090 |
Why?
| | Aged, 80 and over | 3 | 2017 | 151 | 0.090 |
Why?
| | Psychology, Child | 1 | 2010 | 12 | 0.090 |
Why?
| | Social Behavior | 1 | 2010 | 12 | 0.090 |
Why?
| | Rats | 2 | 2001 | 106 | 0.090 |
Why?
| | Attitude of Health Personnel | 1 | 2010 | 42 | 0.090 |
Why?
| | Disclosure | 1 | 2007 | 7 | 0.080 |
Why?
| | Nurse's Role | 1 | 2007 | 10 | 0.080 |
Why?
| | Galvanic Skin Response | 1 | 2007 | 1 | 0.070 |
Why?
| | Heart Rate | 1 | 2007 | 26 | 0.070 |
Why?
| | Self Efficacy | 1 | 2007 | 14 | 0.070 |
Why?
| | Prevalence | 1 | 2007 | 146 | 0.070 |
Why?
| | Syndrome | 1 | 2006 | 34 | 0.070 |
Why?
| | Cohort Studies | 2 | 2019 | 289 | 0.070 |
Why?
| | Chronic Disease | 1 | 2006 | 105 | 0.070 |
Why?
| | Cognition Disorders | 1 | 2006 | 12 | 0.070 |
Why?
| | Incidence | 2 | 2015 | 133 | 0.060 |
Why?
| | Comparative Effectiveness Research | 1 | 2023 | 6 | 0.060 |
Why?
| | Catastrophization | 1 | 2023 | 4 | 0.050 |
Why?
| | Tertiary Healthcare | 1 | 2023 | 4 | 0.050 |
Why?
| | Phobic Disorders | 1 | 2022 | 4 | 0.050 |
Why?
| | Ambulatory Care Facilities | 1 | 2023 | 36 | 0.050 |
Why?
| | Fear | 1 | 2022 | 17 | 0.050 |
Why?
| | Administration, Oral | 1 | 2022 | 58 | 0.050 |
Why?
| | Base Sequence | 2 | 2000 | 81 | 0.050 |
Why?
| | Insurance, Health | 1 | 2022 | 16 | 0.050 |
Why?
| | Homeostasis | 1 | 2001 | 8 | 0.050 |
Why?
| | Sex Factors | 1 | 2022 | 68 | 0.050 |
Why?
| | Pain Perception | 1 | 2021 | 2 | 0.050 |
Why?
| | Professional-Patient Relations | 1 | 2021 | 3 | 0.050 |
Why?
| | Missouri | 1 | 2022 | 81 | 0.050 |
Why?
| | Terminology as Topic | 1 | 2021 | 14 | 0.050 |
Why?
| | Clinical Competence | 1 | 2021 | 29 | 0.050 |
Why?
| | Biological Transport, Active | 1 | 2001 | 4 | 0.050 |
Why?
| | Protein Structure, Tertiary | 1 | 2001 | 14 | 0.050 |
Why?
| | Peptide Fragments | 1 | 2001 | 12 | 0.050 |
Why?
| | Exercise Therapy | 1 | 2021 | 5 | 0.050 |
Why?
| | Patient Dropouts | 1 | 2021 | 1 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2021 | 19 | 0.050 |
Why?
| | Phospholipids | 1 | 2000 | 1 | 0.050 |
Why?
| | Decision Support Techniques | 1 | 2020 | 6 | 0.050 |
Why?
| | Dopamine Antagonists | 1 | 2020 | 3 | 0.050 |
Why?
| | Hypnotics and Sedatives | 1 | 2020 | 6 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 55 | 0.050 |
Why?
| | Quality Improvement | 1 | 2021 | 60 | 0.050 |
Why?
| | Fatty Acids | 1 | 2000 | 2 | 0.050 |
Why?
| | Diet | 1 | 2021 | 52 | 0.050 |
Why?
| | Lipid Metabolism | 1 | 2000 | 9 | 0.050 |
Why?
| | Organic Anion Transporters | 1 | 2000 | 8 | 0.050 |
Why?
| | Tumor Suppressor Proteins | 1 | 2000 | 15 | 0.050 |
Why?
| | Neoplasm Proteins | 1 | 2000 | 31 | 0.050 |
Why?
| | Carrier Proteins | 1 | 2000 | 35 | 0.040 |
Why?
| | Patient Compliance | 1 | 2021 | 55 | 0.040 |
Why?
| | Lipoproteins, LDL | 1 | 1999 | 4 | 0.040 |
Why?
| | Body Mass Index | 1 | 2020 | 157 | 0.040 |
Why?
| | Physical Therapy Modalities | 1 | 2019 | 4 | 0.040 |
Why?
| | Antidepressive Agents | 1 | 2019 | 20 | 0.040 |
Why?
| | DNA Primers | 1 | 1999 | 30 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2012 | 122 | 0.040 |
Why?
| | Models, Psychological | 1 | 2017 | 6 | 0.040 |
Why?
| | Histones | 1 | 2017 | 16 | 0.040 |
Why?
| | Survival Analysis | 1 | 2017 | 50 | 0.040 |
Why?
| | Anxiety | 1 | 2017 | 51 | 0.040 |
Why?
| | Depression | 1 | 2017 | 69 | 0.040 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 66 | 0.040 |
Why?
| | Immunomagnetic Separation | 1 | 2016 | 1 | 0.030 |
Why?
| | Lipids | 1 | 2015 | 8 | 0.030 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2015 | 10 | 0.030 |
Why?
| | Up-Regulation | 1 | 2015 | 25 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2015 | 215 | 0.030 |
Why?
| | Reference Values | 1 | 2015 | 39 | 0.030 |
Why?
| | North Carolina | 1 | 2015 | 3 | 0.030 |
Why?
| | Odds Ratio | 1 | 2015 | 51 | 0.030 |
Why?
| | Aging | 1 | 2015 | 39 | 0.030 |
Why?
| | Logistic Models | 1 | 2015 | 84 | 0.030 |
Why?
| | Paracentesis | 1 | 2013 | 2 | 0.030 |
Why?
| | Walking | 1 | 2014 | 34 | 0.030 |
Why?
| | Disease Management | 1 | 2014 | 34 | 0.030 |
Why?
| | Cadherins | 1 | 2013 | 7 | 0.030 |
Why?
| | Models, Biological | 1 | 2014 | 65 | 0.030 |
Why?
| | Bone Neoplasms | 1 | 2013 | 23 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 99 | 0.030 |
Why?
| | Prostatic Neoplasms | 1 | 2013 | 34 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2012 | 18 | 0.030 |
Why?
| | Overweight | 1 | 2012 | 49 | 0.020 |
Why?
| | Lipoproteins, HDL3 | 2 | 2001 | 2 | 0.020 |
Why?
| | Transfection | 2 | 2001 | 22 | 0.020 |
Why?
| | Molecular Sequence Data | 2 | 2000 | 71 | 0.020 |
Why?
| | Memory | 1 | 2006 | 3 | 0.020 |
Why?
| | Psychomotor Performance | 1 | 2006 | 5 | 0.020 |
Why?
| | Ultrasonography, Doppler, Transcranial | 1 | 2006 | 3 | 0.020 |
Why?
| | Intelligence Tests | 1 | 2006 | 4 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2006 | 15 | 0.020 |
Why?
| | Attention | 1 | 2006 | 13 | 0.020 |
Why?
| | Educational Status | 1 | 2006 | 21 | 0.020 |
Why?
| | Magnetic Resonance Angiography | 1 | 2006 | 9 | 0.020 |
Why?
| | Southeastern United States | 1 | 2005 | 2 | 0.020 |
Why?
| | Regression Analysis | 1 | 2005 | 52 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2005 | 71 | 0.020 |
Why?
| | Cholesterol Oxidase | 1 | 2001 | 1 | 0.010 |
Why?
| | Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent | 1 | 2001 | 1 | 0.010 |
Why?
| | Phospholipases A | 1 | 2000 | 1 | 0.010 |
Why?
| | Sphingomyelins | 1 | 2000 | 1 | 0.010 |
Why?
| | Lipoproteins, HDL2 | 1 | 2000 | 1 | 0.010 |
Why?
| | Phosphatidylcholines | 1 | 2000 | 2 | 0.010 |
Why?
| | Kinetics | 1 | 2000 | 31 | 0.010 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2000 | 1 | 0.010 |
Why?
| | Cross-Linking Reagents | 1 | 2000 | 1 | 0.010 |
Why?
| | Amino Acid Motifs | 1 | 2000 | 2 | 0.010 |
Why?
| | Scavenger Receptors, Class A | 1 | 2000 | 5 | 0.010 |
Why?
| | Biological Transport | 1 | 2000 | 19 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2000 | 32 | 0.010 |
Why?
| | Binding Sites | 1 | 2000 | 26 | 0.010 |
Why?
| | Protein Binding | 1 | 2000 | 31 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2000 | 14 | 0.010 |
Why?
| | Leucine Zippers | 1 | 2000 | 1 | 0.010 |
Why?
| | Helix-Loop-Helix Motifs | 1 | 2000 | 2 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2000 | 7 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2000 | 12 | 0.010 |
Why?
| | I-kappa B Kinase | 1 | 2000 | 4 | 0.010 |
Why?
| | Isoenzymes | 1 | 2000 | 19 | 0.010 |
Why?
| | Cell Line | 1 | 2000 | 81 | 0.010 |
Why?
| | Adrenal Cortex | 1 | 1999 | 1 | 0.010 |
Why?
| | Proteoglycans | 1 | 1999 | 2 | 0.010 |
Why?
| | Arteriosclerosis | 1 | 1999 | 1 | 0.010 |
Why?
| | Apolipoproteins | 1 | 1999 | 5 | 0.010 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|